Penbraya Vaccine for Meningitis Vaccine May Be On the Way
Medically reviewed by Drugs.com.
By Physician’s Briefing Staff HealthDay Reporter
THURSDAY, Oct. 26, 2023 -- A new vaccine recommended Wednesday by independent advisers to the U.S. Centers for Disease Control and Prevention could provide more comprehensive protection from meningitis. The CDC is weighing the advisers' recommendation.
The shot would protect against five types of bacteria causing meningococcal disease, one more than now covered in a single vaccine, CNN reported. Right now, to be protected against all five bacteria types, a person would need four or five shots -- two for MenACWY at age 11 or 12 years and again at 16, and a MenB shot between 16 and 18 years of age.
Penbraya is the new meningococcal vaccine made by Pfizer, CNN reported. This new vaccine, which requires CDC approval, would be for 16- to 23-year-olds who are healthy and those 10 years and older who have increased risks. It consists of two doses, delivered six months apart.
"Penbraya, the first FDA-approved 5-in-1 meningococcal vaccine, provides adolescents and young adults in the U.S. with the most comprehensive protection available against the leading causes of meningococcal disease," Luis Jodar, M.D., Pfizer chief medical affairs officer for vaccines, antivirals, and evidence generation, said in a company statement. He added that Penbraya could help simplify a complex vaccination schedule.
The advisory committee's vote to recommend the shot was 10 to 4, followed by a unanimous vote to add the vaccine to the Vaccines for Children administration plan, CNN reported.
Committee member Kathy Poehling, M.D., a professor of pediatrics and epidemiology and prevention at the Wake Forest School of Medicine in Winston-Salem, North Carolina, was among the no votes. It was not for lack of faith in the vaccine, she said. "We know that there's been tremendous benefit from the vaccines that are being administered. And there's a lot more to learn," Poehling told CNN. "My vote no was because I wanted to vote for a little bit of a broader recommendation. I respect that of my colleagues and believe there are going to be many more conversations to come about meningococcal vaccines."
CNN Article
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted October 2023
Read this next
Higher COVID-19 Vaccination Rates Tied to Decrease in Childhood Asthma Symptoms
WEDNESDAY, July 3, 2024 -- Higher COVID-19 vaccination rates are associated with a lower prevalence of parent-reported childhood asthma symptoms, according to a research letter...
COVID-19 Vaccination Not Tied to Adverse Pregnancy Outcomes
TUESDAY, June 25, 2024 -- mRNA COVID-19 vaccination during pregnancy is not associated with an increased risk of adverse pregnancy outcomes, according to a study published in the...
FDA Approves Capvaxive Pneumococcal 21-Valent Conjugate Vaccine
FRIDAY, June 21, 2024 -- The U.S. Food and Drug Administration has approved the Capvaxive pneumococcal 21-valent conjugate vaccine for the prevention of invasive pneumococcal...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.